指南与共识儿科与产科急症

第452号指南:妊娠期肝内胆汁淤积症的诊断与管理

Guideline No. 452: Diagnosis and Management of Intrahepatic Cholestasis of Pregnancy.
指南 / 共识 · J Obstet Gynaecol Can · 2024-07-31
一句话结论妊娠期肝内胆汁淤积症需用非空腹胆汁酸水平充分诊断,胆汁酸≥100 μmol/L时死胎风险增加,应据此指导优化管理与分娩时机。

本指南由产科护理提供者适用,旨在总结妊娠期肝内胆汁淤积症诊断与管理的当前证据并给出推荐。目标人群为妊娠期肝内胆汁淤积症孕妇。诊断可用空腹或非空腹胆汁酸,需对疾病严重程度分类,确定治疗方案、产前胎儿监测方法及择期分娩时机。患者早产、新生儿呼吸窘迫及新生儿重症监护室入院等不良围产结局风险增加,胆汁酸水平≥100 μmol/L时死胎风险增加。胆汁酸检测可及性和结果及时获取存在不平等,治疗、监测和最终分娩方式存在不确定性;优化诊断和管理方案可改善母儿出生后结局。

要点

  • 妊娠期肝内胆汁淤积症患者胆汁酸水平≥100 μmol/L时死胎风险增加。
  • 诊断可用空腹或非空腹胆汁酸水平,非空腹胆汁酸水平可指导优化管理与分娩时机。
  • 患者早产、新生儿呼吸窘迫和新生儿重症监护室入院等不良围产结局风险增加。
  • 胆汁酸检测可及性和结果及时获取存在不平等,治疗、监测和分娩方式存在不确定性。
  • 优化诊断和管理方案可改善母儿出生后结局。

适用人群与场景

  • 妊娠期肝内胆汁淤积症孕妇。

诊断标准与关键阈值

  • 诊断可使用空腹或非空腹胆汁酸水平。
  • 胆汁酸水平≥100 μmol/L时死胎风险增加。

处置流程与药物剂量

  • 需对疾病严重程度进行分类。
  • 需确定治疗方案。
  • 需确定产前胎儿监测方法。
  • 需确定择期分娩时机。

红旗征与不能漏的情况

  • 胆汁酸水平≥100 μmol/L时死胎风险增加。

研究设计与关键结果

  • 检索Medline、PubMed、Embase和Cochrane Library从建库至2023年3月,使用与妊娠、妊娠期肝内胆汁淤积症、胆汁酸、瘙痒、熊去氧胆酸和死胎相关的MeSH词和关键词。
  • 本文档呈现证据摘要而非方法学综述。
  • 作者使用GRADE方法对证据质量和推荐强度进行分级。

证据类型、等级与局限

  • 证据类型:指南。
  • 证据质量与推荐强度采用GRADE方法分级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 妊娠期肝内胆汁淤积症需用非空腹胆汁酸水平充分诊断,以指导优化管理和分娩时机。
  • 优化诊断和管理方案可改善母儿出生后结局。

指南或共识出处

  • 指南名称:第452号指南:妊娠期肝内胆汁淤积症的诊断与管理。
  • 发布机构:J Obstet Gynaecol Can。
  • 年份:原文未写明。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To summarize the current evidence and to make recommendations for the diagnosis and management of intrahepatic cholestasis of pregnancy.

TARGET POPULATION: Pregnant people with intrahepatic cholestasis of pregnancy.

OPTIONS: Diagnosing the condition using fasting or non-fasting bile acids, classifying disease severity, determining what treatment to offer, establishing how to monitor for antenatal fetal wellbeing, identifying when to perform elective birth.

BENEFITS, HARMS, AND COSTS: Individuals with intrahepatic cholestasis of pregnancy are at increased risk of adverse perinatal outcomes including preterm birth, neonatal respiratory distress and admission to a neonatal intensive care unit, with an increased risk of stillbirth when bile acid levels are ≥100 μmol/L. There is inequity in bile acid testing availability and timely access to results, along with uncertainly of how to treat, monitor. and ultimately deliver these pregnancies. Optimization of diagnostic and management protocols can improve maternal and fetal postnatal outcomes.

EVIDENCE: Medline, PubMed, Embase, and the Cochrane Library were searched from inception to March 2023, using medical subject headings (MeSH) and keywords related to pregnancy, intrahepatic cholestasis of pregnancy, bile acids, pruritis, ursodeoxycholic acid, and stillbirth. This document presents an abstraction of the evidence rather than a methodological review.

VALIDATION METHODS: The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See Appendix A (Tables A1 for definitions and A2 for interpretations).

INTENDED AUDIENCE: Obstetric care providers, including obstetricians, family physicians, nurses, midwives, maternal-fetal medicine specialists, and radiologists.

SOCIAL MEDIA ABSTRACT: Intrahepatic cholestasis of pregnancy requires adequate diagnosis with non-fasting bile acid levels which guide optimal management and delivery timing.

SUMMARY STATEMENTS: RECOMMENDATIONS.

来源:J Obstet Gynaecol Can,查看原文。版权归原作者所有。

参考来源

  1. Hobson SR, Cohen ER, Gandhi S, et al. Guideline No. 452: Diagnosis and Management of Intrahepatic Cholestasis of Pregnancy. J Obstet Gynaecol Can. 2024. PMID: 39089469. doi:10.1016/j.jogc.2024.102618

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。